ERBB2 and breast carcinoma: Our previous pre-clinical comparison of the three approved HER2-targeting TKIs showed that neratinib was the most effective TKI against HER2+ breast cancer models and displayed greater efficacy across multiple cancer types compared to tucatinib and lapatinib [12].